neratinib
Commercial- Indications
- HER2-positive breast cancer, Early stage breast cancer, Metastatic breast cancer
Company intelligence / Profile preview
Bixink Therapeutics
Gangnam-gu, Seoul, South Koreae-crt.org ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Bixink Therapeutics has commercialized NERLYNX (neratinib) for HER2-positive breast cancer in South Korea and is developing multiple digital therapeutics including SparkRx for depression, OC Free for OCD, and attune and DreAMLand for mental health in cancer patients.
- Therapeutic areas
- OncologyPsychiatry
- Modalities
- Small moleculesDigital therapeutics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Puma BiotechnologyBoryungShin Poong PharmLimbix HealthBlue Note Therapeutics
Beyond the preview
Go deeper on Bixink Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bixink Therapeutics.